Literature DB >> 10866100

Choroidopathy of systemic lupus erythematosus.

Q D Nguyen1, H S Uy, E K Akpek, S L Harper, D N Zacks, C S Foster.   

Abstract

PURPOSE: To describe the ocular and systemic manifestations associated with systemic lupus erythematosus (SLE) choroidopathy.
METHODS: Three new cases of choroidopathy in patients with active SLE were described. Twenty-five published cases of lupus choroidopathy were summarized.
RESULTS: There have been 28 cases of lupus choroidopathy (47 involved eyes) that have been reported in the English literature since 1968, including the three current cases. Only two of the patients were male. The choroidopathy was bilateral in 19 patients (68%). All 28 patients (100%) had active systemic vascular disease at the onset of their choroidopathy; 18 (64%) had nephropathy and 10 (36%) had central nervous system (CNS) lupus vasculitis. All but one of the patients had a known diagnosis of SLE at the onset of choroidopathy. 30 of the 47 involved eyes had presenting visual acuity of 20/40 or better; 14 eyes showed improvement in visual acuity with therapy. 23 patients (82%) had resolution of their choroidopathy when their systemic disease was brought under control. Despite treatment, 4 of the 28 patients (14%) died from complications of SLE.
CONCLUSIONS: Although less known than retinopathy, lupus choroidopathy may be more common than generally appreciated. It usually serves as a sensitive indicator of lupus activity. The presence of SLE choroidopathy is generally indicative of coexistent (although sometimes occult) nephropathy, CNS vasculitis, and other SLE visceral lesions. Immunomodulation of the systemic disease can lead to improvement and resolution of the systemic vasculitis as well as the choroidopathy.

Entities:  

Mesh:

Year:  2000        PMID: 10866100     DOI: 10.1191/096120300680199024

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  23 in total

1.  [Choroidal vascular occlusion].

Authors:  D A Märker; A Walter; H Helbig
Journal:  Ophthalmologe       Date:  2011-01       Impact factor: 1.059

2.  Hypopyon uveitis associated with systemic lupus erythematosus and antiphospholipid antibody syndrome.

Authors:  Jeffrey M Zink; Rita Singh-Parikshak; C Starck Johnson; David N Zacks
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-10-13       Impact factor: 3.117

3.  Acute lupus choroidopathy: multimodal imaging and differential diagnosis from central serous chorioretinopathy.

Authors:  Murat Hasanreisoglu; Gokcen D Gulpinar Ikiz; Hamit Kucuk; Ozkan Varan; Sengul Ozdek
Journal:  Int Ophthalmol       Date:  2017-01-03       Impact factor: 2.031

4.  Retinal thickness and microvascular alterations in the diagnosis of systemic lupus erythematosus: a new approach.

Authors:  Ren Liu; Yan Wang; Qiang Xia; Tian Xu; Ting Han; Shuang Cai; Shui-Lin Luo; Rui Wu; Yi Shao
Journal:  Quant Imaging Med Surg       Date:  2022-01

Review 5.  Systemic lupus erythematosus and ocular involvement: an overview.

Authors:  Rosanna Dammacco
Journal:  Clin Exp Med       Date:  2017-12-14       Impact factor: 3.984

Review 6.  Ocular involvement in connective tissue disorders.

Authors:  Stephanie Young
Journal:  Curr Allergy Asthma Rep       Date:  2005-07       Impact factor: 4.919

Review 7.  Ocular vasculitis.

Authors:  J Banks Shepherd
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.686

8.  Ocular manifestations of systemic lupus erythematosus: a review of the literature.

Authors:  Neal V Palejwala; Harpreet S Walia; Steven Yeh
Journal:  Autoimmune Dis       Date:  2012-07-02

9.  Choroidopathy and kidney disease: a case report and review of the literature.

Authors:  Nirav V Kamdar; Amsalu Erko; Jason S Ehrlich; Jonathan W Kim; Neeraja Kambham; Glenn M Chertow
Journal:  Cases J       Date:  2009-05-12

10.  [Choroidopathy of systemic lupus erythematosus: about a case].

Authors:  Benatiya Andaloussi Idriss; Chraibi Fouad; Bhallil Salima; Abdellaoui Meryem; Tahri Hicham
Journal:  Pan Afr Med J       Date:  2013-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.